Evidence map›Paper›PMID 41887669›Full record

Trial reportThe European respiratory journal2026

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Marlies S Wijsenbeek, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold, Toby M Maher, Fernando J Martinez, Justin M Oldham, Luca Richeldi, Claudia Valenzuela and 5 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Marlies S WijsenbeekCenter of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands m.wijsenbeek-lourens@erasmusmc.nl.ORCID https://orcid.org/0000-0002-4527-6962
Shervin AssassiDivision of Rheumatology, McGovern Medical School, UTHealth Houston, Houston, TX, USA.ORCID https://orcid.org/0000-0002-8059-9978
Arata AzumaClinical Research Center, Mihara General Hospital, Saitama, Japan.ORCID https://orcid.org/0000-0003-0506-9966
Vincent CottinNational Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.ORCID https://orcid.org/0000-0002-5591-0955
Anna-Maria Hoffmann-VoldDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0001-6467-7422
Toby M MaherDepartment of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-7192-9149
Fernando J MartinezUniversity of Massachusetts (UMass) Chan Medical School/UMass Memorial Health System, Worcester, MA, USA.
Justin M OldhamPulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Luca RicheldiUnità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID https://orcid.org/0000-0001-8594-1448
Claudia ValenzuelaPulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain.ORCID https://orcid.org/0000-0002-0856-6290
Hui GuBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Ivana RitterBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Susanne StowasserBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Michael KreuterCenter for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
FIBRONEER-ILD Trial Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9 mg twice daily and 18 mg twice daily (hereafter nerandomilast 9 mg and 18 mg, respectively) reduced the decline in forced vital capacity at week 52 compared with placebo (primary end-point). We assessed the effects of nerandomilast up to the final database lock.

methodsTime to first acute exacerbation of interstitial lung disease, hospitalisation for respiratory cause or death (key secondary end-point) and other time-to-event end-points were assessed.

results1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At the final database lock, the mean±sd exposure to trial medication was 15.1±5.7 months and the mean±sd observation period was 17.0±4.1 months. Compared with placebo, the hazard ratio for the key secondary end-point was 0.78 (95% CI 0.61-1.00) for nerandomilast 9 mg and 0.77 (95% CI 0.60-0.99) for nerandomilast 18 mg; hazard ratios were lower among patients not taking nintedanib (0.69 (95% CI 0.49-0.97) and 0.65 (95% CI 0.46-0.92), respectively) than among those taking background nintedanib (0.90 (95% CI 0.63-1.30) and 0.93 (95% CI 0.65-1.34), respectively). For death, the hazard ratio

conclusionsIn the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.

Indexed as

IndolesPulmonary FibrosisAgedCyclobutanesDisease ProgressionDouble-Blind MethodFemaleFollow-Up StudiesHospitalizationHumansMaleMiddle AgedPiperidinesProportional Hazards ModelsTreatment OutcomeVital CapacityCyclobutanesIndolesnerandomilastnintedanibPiperidines

Identifiers

PMID41887669
PMCPMC13347714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.